Merck wants to double supply of its COVID drug

Tuesday, 12. October 2021 06:20

Merck & Co. Inc. unveiled that it intends to double its production capacity for molnupiravir, the investigational oral medicine against COVID-19 which it developed with Ridgeback Biotherapeutics.

"We are doing these special purchase agreements as a sort of initial way to get therapy to people as quickly as possible in certain countries and there's a large number of them that we're working through," Merck's senior vice-president of clinical research, Nicholas Kartsonis, said to the Financial Times.

Merck has secured procurement deals with Singapore, New Zealand, Australia and South Korea, while also filing for approval with the United States Food and Drug Administration.

Related Links: 
Author:
Breaking the News / BU